Elicera Therapeutics AB
STO:ELIC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Elicera Therapeutics AB
Capital Expenditures
Elicera Therapeutics AB
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Elicera Therapeutics AB
STO:ELIC
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Capital Expenditures
-kr3.6m
|
CAGR 3-Years
41%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Capital Expenditures
-kr5.2m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Capital Expenditures
-kr247m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
-27%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Capital Expenditures
-kr3.2B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-36%
|
|
|
BioArctic AB
STO:BIOA B
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Elicera Therapeutics AB
Glance View
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
